EC Microbiology

Review Article Volume 19 Issue 10 - 2023

COVID-19 Infection is Associated with Worsening of the Quality of Life in Obesity, Diabetes, and Hypertension Patients: Alteration of the Immune Response May be the Underlying Mechanism

Karan Singh1*, Akash Gujaral1, Debashis Dutta2, Alok Tiwary3 and Faizan Danish1

1New York University (NYU) Langone Health Center, NYU Robert I Grossman School of Medicine, New York, NY, USA

2Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA

3Department of Pharmacology and Experimental Neurosciences, College of Medicine, University of Nebraska Medical Center, Omaha, NE USA

*Corresponding Author: Karan Singh, New York University (NYU) Langone Health Center, NYU Robert I Grossman School of Medicine, New York, NY, USA.
Received: October 20, 2023; Published: November 03, 2023




Obesity and diabetes are complex syndromes caused by an intricate combination of genes and environmental interactions. Higher blood glucose levels in people affected with diabetes diminishes the immune potential to tackle infections. This puts individuals with diabetes at a higher risk of developing relatively worse symptoms once they contract SARS-CoV-2. Moreover, the higher mortality rate in patients with at least one of these comorbidities ignites a major public health concern at a global level. It has been known that people with underlying disorders like hypertension, obesity, diabetes, coronary artery, respiratory disease, kidney problems, etc. are at a higher risk of developing severe illness after SARS-CoV-2 infection. As of November 22, 2020 SARS-CoV-2 infection has spread to more than 57.8 million people and has claimed 1.3 million lives. More than a quarter of these cases had been pre-diagnosed with diabetes, obesity, or hypertension. Needless to say, the ratio increases when comparing fatality in the normal versus obese or diabetic population. This review aims to provide an elaborate mechanism of the above-mentioned comorbidities in COVID-19.

 Keywords: Coronavirus; Inflammatory Cytokines; Coronary Artery Diseases; Respiratory Illness; Obesity; Diabetes; Cardiovascular Disease (CVD); Myocarditis; COVID-19; SARS-CoV-2

  1. Wu Z and McGoogan JM. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention”. The Journal of the American Medical Association 323 (2020): 1239-1242.
  2. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
  3. Hussain A., et al. “COVID-19 and diabetes: Knowledge in progress”. Diabetes Research and Clinical Practice 162 (2020): 108142.
  4. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
  5. Ceccarelli M., et al. “Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?” European Review for Medical and Pharmacological Sciences 24 (2020): 2781-2783.
  6. Zheng X., et al. “Clinical Features and Risk Factors for the Severity of Inpatients with COVID-19: A Retrospective Cohort Study”. SSRN Electronic Journal (2020).
  7. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. The Lancet (2020): 1054-1062.
  8. Chen H., et al. SARS-CoV-2 activates lung epithelia cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients by single-cell sequencing (2020).
  9. Yao X-H., et al. “Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient”. Cell Research 30 (2020): 541-543.
  10. Albuquerque D., et al. “The contribution of genetics and environment to obesity”. British Medical Bulletin (2017): 159-173.
  11. Stamou S and Kozanidis L. Impact of search results on user queries. Proceeding of the eleventh international workshop on Web information and data management - WIDM (2009).
  12. Busetto L., et al. “Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management”. Obesity Facts (2017): 597-632.
  13. Products - Data Briefs - Number 360 (2020).
  14. National Diabetes Statistics Report | Data and Statistics | Diabetes | CDC (2020).
  15. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200511-covid-19-sitrep-112.pdf?sfvrsn=813f2669_2
  16. Richardson S., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area”. The Journal of the American Medical Association (2020).
  17. Guan W-J., et al. “Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis”. European Respiratory Journal (2020): 2000547.
  18. Yan Y., et al. “Clinical characteristics and outcomes of patients with severe covid-19 with diabetes”. BMJ Open Diabetes Research and Care 8 (2020): e001343.
  19. Spiezia L., et al. “COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure”. Thrombosis and Haemostasis 120 (2020): 998-1000.
  20. Berbudi A., et al. “Type 2 Diabetes and its Impact on the Immune System”. Current Diabetes Reviews (2019).
  21. Ferlita S., et al. “Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis”. Journal of Clinical Medicine (2019): 2219.
  22. Messina G., et al. “Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work”. International Journal of Molecular Sciences (2020): 21.
  23. Iwata M., et al. “Ratio of low molecular weight serum adiponectin to the total adiponectin value is associated with type 2 diabetes through its relation to increasing insulin resistance”. PLoS One 13 (2018): e0192609.
  24. Menzaghi C., et al. “Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study”. Journal of Internal Medicine (2010): 287-294.
  25. Acharya SD., et al. “Total and high-molecular-weight adiponectin levels in relation to insulin resistance among overweight/obese adults”. Central Asian Journal of Global Health 2 (2013): 55.
  26. Ouchi N and Walsh K. “Adiponectin as an anti-inflammatory factor”. Clinica Chimica Acta (2007): 24-30.
  27. Higgins LS and Mantzoros CS. “The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer”. Peroxisome Proliferator Activated Receptor Research (2008): 936906.
  28. Cowan LT., et al. “Inpatient and Outpatient Infection as a Trigger of Cardiovascular Disease: The ARIC Study”. Journal of the American Heart Association 7 (2018): e009683.
  29. Madjid M., et al. “Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects”. European Heart Journal 28 (2007): 1205-1210.
  30. Dhainaut J-F., et al. “Underlying Disorders and Their Impact on the Host Response to Infection”. Clinical Infectious Diseases (2005): S481-S489.
  31. Fauci AS., et al. “Covid-19 - Navigating the Uncharted”. The New England Journal of Medicine (2020): 1268-1269.
  32. Gao Q., et al. “The Epidemiological Characteristics of 2019 Novel Coronavirus Diseases (COVID-19) in Jingmen, China”. SSRN Electronic Journal (2020).
  33. Madjid M and Casscells SW. “Of birds and men: cardiologists’ role in influenza pandemics”. Lancet 364 (2004): 1309.
  34. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
  35. Clerkin KJ., et al. “COVID-19 and Cardiovascular Disease”. Circulation 141 (2020): 1648-1655.
  36. Hypertension (2020).
  37. Knudsen L and Ochs M. “The micromechanics of lung alveoli: structure and function of surfactant and tissue components”. Histochemistry and Cell Biology 150 (2018): 661-676.
  38. Weibel ER. “Morphological basis of alveolar-capillary gas exchange”. Physiological Reviews 53 (1973): 419-495.
  39. Maina JN and West JB. “Thin and strong! The bioengineering dilemma in the structural and functional design of the blood-gas barrier”. Physiological Reviews 85 (2005): 811-844.
  40. Fehrenbach H. “Alveolar epithelial type II cell: defender of the alveolus revisited”. Respiratory Research 2 (2001): 33-46.
  41. Mason RJ. “Pathogenesis of COVID-19 from a cell biology perspective”. European Respiratory Journal (2020): 55.
  42. Sungnak W., et al. “SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes”. Nature Medicine 26 (2020): 681-687.
  43. Bertram S., et al. “Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts”. PLoS One 7 (2012): e35876.
  44. Zou X., et al. “Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection”. Frontiers in Medicine 14 (2020): 185-192.
  45. Qi F., et al. “Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses”. Biochemical and Biophysical Research Communications 526 (2020): 135-140.
  46. Wu C., et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue (2020).
  47. Rockx B., et al. “Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model”. Science 368 (2020): 1012.
  48. Wang D., et al. “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. The Journal of the American Medical Association (2020).
  49. Yin Y and Wunderink RG. “MERS, SARS and other coronaviruses as causes of pneumonia”. Respirology (2018): 130-137.
  50. Wen W., et al. “Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing”. Cell Discovery 6 (2020): 1-18.

Karan Singh., et al. “COVID-19 Infection is Associated with Worsening of the Quality of Life in Obesity, Diabetes, and Hypertension Patients: Alteration of the Immune Response May be the Underlying Mechanism”. EC Microbiology  19.10 (2023): 01-08.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net